Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
- 245 Downloads
In the primary core analysis of BIG 1–98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive (HR+) early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced the risk of breast cancer recurrence by 28% and distant recurrence by 27%.
A Markov model was used to estimate the incremental cost per quality-adjusted life year (QALY) gained with 5 years of initial adjuvant therapy with letrozole versus tamoxifen from a Canadian healthcare system perspective. Probabilities of recurrence and side effects for tamoxifen were based on published results of BIG 1–98 and other published population-based studies. Corresponding probabilities for letrozole were calculated by multiplying probabilities for tamoxifen by estimated relative risks for letrozole versus tamoxifen from BIG 1–98. Other probabilities, costs of breast-cancer care and treatment of side effects, and health-state utilities were obtained from published studies. Costs and QALYs were estimated over the lifetime of a cohort of postmenopausal women with HR+ early breast cancer, aged 60 years at initiation of therapy, and discounted at 5% annually.
Compared with tamoxifen, letrozole yields an additional 0.368 life-years (12.453 vs. 12.086) and 0.343 QALYs (11.582 vs. 11.239). These benefits are obtained at an additional cost of $Can 8,110 ($Can 30,819 vs. $Can 22,709). Cost per QALY gained for letrozole versus tamoxifen is $Can 23,662 (95% CI $Can 15,667–$Can 52,014).
In postmenopausal women with HR+ early breast cancer, initial adjuvant treatment with letrozole is cost-effective from the Canadian healthcare system perspective.
KeywordsAdjuvant therapy Breast cancer Cost-effectiveness Letrozole Tamoxifen
- 1.Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467Google Scholar
- 2.Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21(11):2101–2109PubMedCrossRefGoogle Scholar
- 3.Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271PubMedCrossRefGoogle Scholar
- 4.Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19(18):3808–3816PubMedGoogle Scholar
- 5.The Breast International Group (BIG) 1–98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757Google Scholar
- 6.Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 25(5):486–492 Epub January 2PubMedCrossRefGoogle Scholar
- 8.Goldie SJ (2003) Chapter 15: Public health policy and cost-effectiveness analysis. J Natl Cancer Inst Monogr (31):102–110Google Scholar
- 10.Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) ISPOR Task Force on Good Research Practices-Modeling Studies: principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6:9–17PubMedCrossRefGoogle Scholar
- 11.Statistics US: Table 326–0002—Consumer price index (CPI), 2001 basket content, annual. Available at: http: //www.statcan.ca. Accessed April 4, 2006Google Scholar
- 13.Howell A, on behalf of the ATAC Trialists’ Group (2004) The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer—updated efficacy results based on a median follow-up of 5 years. Abstract No. 1, San Antonio Breast Cancer Symposium Google Scholar
- 14.Rocchi A, Verma S (2006) Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 14(9):917–927. Epub ahead of printGoogle Scholar
- 15.Locker GY, on behalf of the ATAC Trialists’ Group (2004) Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare system perspective: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. 27th Annual San Antonio Breast Cancer Symposium, December 8–11, 2004. Abstract 2085Google Scholar
- 21.Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF, Thurlimann B, Cavalli F, Obrecht JP et al (1994) First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation.J Clin Oncol 12:2071–2077PubMedGoogle Scholar
- 24.National Cancer Institute: U.S. National Institutes of Health (2006) SEER Public Use Data, 1973–2002. Available at: http: //www.seer.cancer.gov. Accessed April 4, 2006Google Scholar
- 29.American Heart Association: Heart Disease and Stroke Statistics (2005) Update. American Heart Association, Dallas, TexasGoogle Scholar
- 31.Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
- 33.Statistics Canada: Canadian Vital Statistics, Death Database. Available at: http: //www.statcan.ca. Accessed April 4, 2006Google Scholar
- 40.Brogan database: Available at: http: //www.broganinc.com. Accessed March 2006Google Scholar
- 53.Bank of Canada. Rates and Statistics (2007) Daily Currency Converter. Availalbe at: http: //www.bankofcanada.ca/en/rates/converter.html. Accessed April 12, 2007Google Scholar
- 55.Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473–481Google Scholar
- 56.Laupacis A, Feeny D, Detsky AS, Tugwell PX (1993) Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J 148:927–929Google Scholar
- 59.Delea T, Smith R, Karnon J (2002) Cost-effectiveness of letrozole vs tamoxifen as 1st line hormonal therapy for postmenopausal women with advanced breast cancer: the US perspective. 25th Annual San Antonio Breast Cancer Symposium; December 11–14, 2002. Abstract 542Google Scholar
- 64.National Institute for Health and Clinical Excellenc (2006) Final appraisal determination—Hormonal therapies for the adjuvant treatment of early oestrogen receptor. Positive breast cancer. Issue date: August 2006. Available at: http: //www.nice.org.uk/page.aspx?o=63296. Accessed October 4, 2006Google Scholar
- 65.Cuzick J, Sasieni P, Howell A (2006) Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 94:460–464. doi:10.1038/sj.bjc.6602964 Published online January 24, 2006Google Scholar